Hemlibra is a medication used to treat hemophilia A, a genetic disorder causing deficiency in clotting factor VIII. It is a monoclonal antibody that mimics clotting factor VIII by binding to activated factor IX and factor X and increasing blood clotting, reducing the risk of bleeding. Hemlibra is innovative because it can be used as both preventative and for the treatment of bleeding episodes, unlike previous treatments that relied on clotting factor VIII infusions. Hemlibra can reduce bleeding episodes in individuals with hemophilia A and has been shown to improve the quality of life and decrease joint damage. Hemlibra has some potential side effects, and individuals should discuss the risks and benefits with their healthcare provider.